Solanezumab - Eli Lilly and Company
Alternative Names: Anti-amyloid-beta monoclonal antibody - Eli Lilly and Company; Anti-Aβ monoclonal antibody - Eli Lilly and Company; LY 2062430Latest Information Update: 05 Nov 2023
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly; Eli Lilly and Company
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Alzheimer's disease
Most Recent Events
- 16 Jul 2023 Additional adverse events data from a phase III trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)
- 08 Jun 2023 Eli Lilly and Company and Alzheimer's Therapeutic Research Institute completes a phase III trial for Alzheimer's disease (Early-stage disease, In the elderly, Preclinical asymptomatic Alzheimer's disease) in Japan, Canada, Australia, USA (IV) (NCT02008357)
- 08 Mar 2023 Efficacy and adverse events data from a phase III trial in Alzheimer's disease released by Eli Lilly and Company